Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
reboxetine + oxybutynin
- Development stage
- Phase 3
- Lead developer
- Apnimed
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
AD128 is an investigational oral pharmaceutical combination therapy under development for the treatment of obstructive sleep apnea. It consists of reboxetine, a selective norepinephrine reuptake inhibitor, and oxybutynin, a selective antimuscarinic agent. The drug is designed to target the neurologic control of upper airway muscles during sleep, aiming to maintain airway patency in patients with obstructive sleep apnea. AD128 is being developed by Apnimed and has been evaluated in clinical trials for its efficacy in reducing the severity of obstructive sleep apnea[1][2][3][4].
- Brand names
- Edronax + Ditropan
- Other names
- AD128AD-128AD 128
02
Targets
M1 (Muscarinic acetylcholine receptor M1)CHRM2 (M2)CHRM3 (M3)NET (Norepinephrine Transporter)
Beyond the preview
Go deeper on reboxetine + oxybutynin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on reboxetine + oxybutynin.